论文部分内容阅读
炎症性肠病(inflammatory bowel disease,IBD)是一种非特异性的肠道炎症性疾病,包括溃疡性结肠炎和克罗恩病,以慢性过程、反复发作、病因未明为其特征。西方国家发病率较高,国内发病有上升趋势。近年来研究认为,IBD是由免疫反应介导、遗传为基础以及环境因素等多因素相互作用的结果[1]。1966年Bloom和Bennett等首次鉴定了一种由活化的T淋巴细胞分泌的可抑制巨噬细胞/单核细胞移动的细胞因子,命名为巨噬细胞移动抑制因子(macrophage migration inhibition factor,MIF)。MIF具有多种生物活性,它既是一种前炎性细胞因子,又是一种源于垂体的激素[2],是先天性免疫和获得性免疫的重要调节因子。近年来,国外研究发现[3]MIF参与炎症性肠病的发生发展,现综述如下。
Inflammatory bowel disease (IBD) is a nonspecific intestinal inflammatory disease, including ulcerative colitis and Crohn’s disease, characterized by chronic processes, recurrent episodes, and etiology. Western countries have a higher incidence, the incidence of domestic upward trend. In recent years, studies suggest that IBD is mediated by immune response, genetic basis and environmental factors and other multi-factorial interaction results [1]. In 1966, Bloom and Bennett first identified a cytokine secreted by activated T lymphocytes that inhibits the migration of macrophages / monocytes, and named it macrophage migration inhibition factor (MIF). MIF has a variety of biological activity, it is a pro-inflammatory cytokines, but also a hormone derived from the pituitary [2], is an important regulator of innate immunity and adaptive immunity. In recent years, foreign studies have found [3] MIF involved in the occurrence and development of inflammatory bowel disease, are summarized below.